Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds

Hatteras Venture Partners 在两支专注于医疗保健的基金中筹集了超过 2 亿美元的资金

– Invests in 100th Portfolio Company, Celebrates 25th Year of Franchise Operation –

– 投资第100家投资组合公司，庆祝特许经营运营25周年 –

– Announces Promotion of Lauren Flickinger and Ben Scruggs, Ph.D., as Partners –

- 宣布晋升Lauren Flickinger和Ben Scruggs博士为合伙人 -

DURHAM, N.C., August 13, 2025-- Hatteras Venture Partners announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I) with over $200 million in capital commitments from limited partners. The fund closings come at a time as Hatteras has invested in its 100th portfolio company and marks 25 years of building transformational human medicine companies that benefit patients and the professionals who serve them..

北卡罗来纳州达勒姆，2025年8月13日 —— Hatteras Venture Partners 宣布了 Hatteras Venture Partners VII（HVP VII）和 Hatteras Opportunity Fund I, LP（HOF I）的最终募集结束，获得了有限合伙人超过2亿美元的资本承诺。此次基金募集完成之际，正值 Hatteras 投资其第100家投资组合公司，并标志着其在创立变革性人类医药公司方面已历经25年，这些公司造福了患者及为其服务的专业人士。

“Last week, our portfolio company, HistoSonics, announced its strategic acquisition in a landmark transaction. Across 100 portfolio companies and 25 years, we’ve had our share of exhilarating wins like this, along with heartbreaking disappointments,” said Clay Thorp, General Partner of Hatteras Venture Partners.

“上周，我们的投资组合公司 HistoSonics 在一宗具有里程碑意义的交易中宣布了其战略性收购。在拥有100家投资组合公司的25年里，我们经历了许多像这样的令人振奋的成功，也有过令人心碎的失望，”Hatteras Venture Partners 的普通合伙人 Clay Thorp 表示。

“What has been most gratifying in this journey is the relationships we have made with scholarly innovators, committed entrepreneurs, and resilient co-investors. We look forward to continuing to invest in transformative life sciences companies disrupting the status quo in healthcare and accelerating the pace of innovation.”.

“在这段旅程中，最令人欣慰的是我们与学术创新者、有奉献精神的企业家和坚韧的共同投资者建立了关系。我们期待继续投资于变革生命科学公司，打破医疗保健领域的现状，加快创新步伐。”

Track Record of Success

成功记录

Hatteras began in 2000 with the closing of Hatteras Venture Partners I, LP, a seed-stage venture fund with $2.93 million in capital. Today, the firm manages over $900 million in capital focused on seed- and early-stage companies in the health innovation sectors of biotechnology, medtech, and healthtech..

Hatteras 于2000年成立，当时 Hatteras Venture Partners I, LP 这家种子阶段的风险基金完成了募集，资金规模为293万美元。如今，该公司管理着超过9亿美元的资本，专注于生物技术、医疗技术和健康技术领域的种子期和早期创新企业。

Across HVP I to HVP VII, the following are highlights of several of the exciting companies Hatteras has been a part of:

在HVP I到HVP VII中，以下是哈特拉斯参与的几家令人兴奋的公司的亮点：

• HistoSonics, Inc. pioneered the development of histotripsy, a completely new modality for tissue destruction using ultrasound. Its Edison® Histotripsy System was FDA approved in October 2023 for the destruction of liver tumors. Since then, the company has seen a highly successful launch in hospitals and health systems across the United States.

• HistoSonics公司开创了组织破坏全新模式——利用超声波的组织消融技术（histotripsy）。其Edison® Histotripsy系统于2023年10月获得FDA批准，用于肝肿瘤的治疗。自那时起，该公司在美国各地的医院和医疗系统中取得了极为成功的推广。

Hatteras co-led HistoSonics’s Series A round in December 2009. HistoSonics recently announced a strategic transaction in which the company was acquired for $2.25 billion..

2009年12月，Hatteras联合领投了HistoSonics的A轮融资。HistoSonics最近宣布了一项战略性交易，该公司被以22.5亿美元收购。

• Kymera Therapeutics, Inc. is arguably the leading targeted protein degradation company in the biotechnology industry. Hatteras participated in the Series B round of the company, which later closed a very successful crossover round, a strategic deal with Sanofi, and an IPO in 2020. Today, Kymera has multiple high-value drugs in development and is publicly traded with a market capitalization greater than $3 billion..

• Kymera Therapeutics, Inc.可以说是生物技术行业中领先的靶向蛋白质降解公司。Hatteras参与了该公司的B轮融资，随后该公司成功完成了交叉轮融资、与赛诺菲达成战略交易，并于2020年进行了首次公开募股（IPO）。如今，Kymera拥有多个高价值药物正在开发中，并已公开上市，市值超过30亿美元。

• G1 Therapeutics, Inc. developed a first-in-class CDK 4/6 inhibitor, trilaciclib, for the protection of bone marrow during chemotherapy. Hatteras was the lead investor of the company’s seed round, assumed interim management, and co-led the syndication for all rounds through to its $105 million IPO in 2017, at which point Hatteras owned 16% of the company.

• G1 Therapeutics公司开发了首个CDK 4/6抑制剂曲拉西利，用于在化疗期间保护骨髓。Hatteras是该公司种子轮的主要投资者，承担了临时管理职责，并共同领导了所有轮融资，直至其在2017年实现1.05亿美元的IPO，在此阶段Hatteras拥有公司16%的股份。

Ultimately, G1 achieved a market capitalization greater than $2 billion, trilaciclib was approved as Cosela® in 2021, and the company was acquired by Pharmacosmos in 2024..

最终，G1 的市值超过了 20 亿美元，Trilaciclib 在 2021 年被批准为 Cosela®，该公司于 2024 年被 Pharmacosmos 收购。

• Jumo Health, Inc. became the thought leader in health education for clinical trials. Hatteras led the Series B round in the company and led its transition from a paper-based graphic novel provider to a fully integrated, digital content company. Jumo was acquired in 2024 by Falfurias, resulting in a greater than 7 times return for Hatteras..

Jumo Health, Inc. 成为临床试验健康教育领域的思想领袖。Hatteras 领导了该公司的 B 轮融资，并引领其从一家基于纸质的漫画小说提供商转型为一家完全集成的数字内容公司。Jumo 于 2024 年被 Falfurias 收购，为 Hatteras 带来了超过 7 倍的回报。

• Iris Healthcare, Inc. is a leader in the development of comprehensive care plans for patients nearing the end of life. The company provided an integrated program of advanced care planning and communication between providers, patients, and their families. Hatteras led the Series B round of Iris in 2019, which catalyzed the company’s commercial progress and the proof of its model.

Iris Healthcare, Inc. 是为生命接近终点的患者制定全面护理计划的领军企业。该公司提供了一套综合性的高级护理规划和沟通方案，连接医疗服务提供者、患者及其家属。Hatteras 于2019年领投了Iris的B轮融资，推动了公司的商业化进程并验证了其模式的可行性。

Iris was acquired by Aledade in 2023, resulting in a greater than 7 times return for Hatteras..

2023年，Iris被Aledade收购，为Hatteras带来了超过7倍的回报。

• Asthmatx, Inc. developed a first-in-class medical device to treat asthma through RF ablation of the airway smooth muscle. Hatteras was a co-lead investor in the Series B investment as a part of its partnership with HBM. Asthmatx’s Alair® Bronchial Thermoplasty System gained FDA approval, and the company was acquired in 2010 by Boston Scientific for $194 million plus $250 million in earnout payments..

Asthmatx公司开发了首个通过射频消融气道平滑肌来治疗哮喘的医疗器械。Hatteras作为与HBM合作的一部分，是B轮融资的共同领投者。Asthmatx的Alair®支气管热成形系统获得了FDA的批准，并于2010年被波士顿科学公司以1.94亿美元收购，另加2.5亿美元的盈利支付。

• Synthematix, Inc. was the first Hatteras investment. Launched in 2000, the company became a pioneer in the field of electronic laboratory notebooks. Hatteras was the founding investor and played a leadership role in management. The company was sold to Symyx Technologies in 2005 for $13 million plus $4 million in earnouts..

• Synthematix, Inc. 是 Hatteras 的第一笔投资。该公司于2000年成立，成为电子实验室笔记本领域的先驱。Hatteras 作为创始投资者，在管理中发挥了领导作用。公司于2005年以1300万美元外加400万美元的盈利支付被出售给 Symyx Technologies。

Strengthening Team with an Eye Towards the Next 25 years

着眼于未来25年，强化团队建设

In addition to building the Hatteras capital base, the firm has made two important promotions within its team. Ben Scruggs, Ph.D., has been promoted from Principal to Partner with a focus on biopharmaceuticals and tools investments. Ben has been concurrently leading portfolio company, Altis Biosystems, as CEO.

除了建立哈特拉斯资本基础外，该公司还在其团队内进行了两项重要晋升。本·斯克鲁格斯博士已从首席晋升为合伙人，专注于生物制药和工具投资。同时，本还兼任投资组合公司Altis Biosystems的首席执行官。

Altis is an emerging leader in the “organ-on-a-chip” field, a stated priority area for the U.S. FDA..

Altis 是“芯片上的器官”领域的新兴领导者，这是美国 FDA 重点优先发展的领域。

In addition, Hatteras has promoted Lauren Flickinger from Principal to Partner. Lauren joined Hatteras in 2021 from Morgan Stanley, where she was an investment banker. She is the Fund Manager of the Hatteras-managed Pisgah Fund in Asheville, N.C. and is a leader in building Hatteras’s health technology portfolio..

此外，哈特拉斯已将劳伦·弗利金格从主要负责人晋升为合伙人。劳伦于2021年从摩根士丹利加入哈特拉斯，曾担任投资银行家。她是哈特拉斯管理的北卡罗来纳州阿什维尔皮斯加基金的基金经理，并且是哈特拉斯健康技术组合建设的领导者。

“Ben and Lauren possess the values, instincts, and tenacity we need to lead Hatteras into the future,' said John Crumpler, Co-Founder and General Partner of Hatteras Venture Partners. “The opportunity for them to lead new deals and harvest existing investments in HVP VII is tremendous, and I look forward to continuing our work together as they step into these expanded leadership roles.”.

“本和劳伦拥有我们带领哈特拉斯走向未来所需的价值观、本能和坚韧，”哈特拉斯风险合伙公司联合创始人兼普通合伙人约翰·克拉姆勒表示。“他们领导新交易和收获HVP VII现有投资的机会非常巨大，我期待在他们步入这些扩展的领导角色时继续我们的合作。”

About Hatteras Venture Partners

关于哈特拉斯风险合伙人

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, N.C. with a focus on seed- and early-stage opportunities in biopharmaceuticals, medical devices, and health technology companies in human medicine. The firm has over $900 million under management in seven venture capital funds.

Hatteras Venture Partners是一家位于北卡罗来纳州研究三角园区的风险投资公司，专注于人类医学领域中的生物制药、医疗器械和健康技术公司的种子期和早期投资机会。该公司管理着七只风险投资基金，管理资产超过9亿美元。

Hatteras is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed- and early-stage investing and company formation. To learn more about Hatteras Venture Partners, please visit www.hatterasvp.com and follow us on LinkedIn..

Hatteras 由一支经验丰富的企业家和运营者团队领导，拥有种子期和早期投资及公司组建的长期成功记录。如需了解有关 Hatteras Venture Partners 的更多信息，请访问 www.hatterasvp.com 并在 LinkedIn 上关注我们。